LCN2 Antibody Therapy Shows Promise in Lung, Pancreatic Cancer Mouse Models
Event summary
- NYU Langone Health researchers identified lipocalin 2 (LCN2) as a protein released by stressed cancer cells that helps tumors evade the immune system.
- Blocking LCN2 with an antibody therapy in mice slowed tumor growth and increased T-cell infiltration, demonstrating improved efficacy when combined with existing immunotherapies.
- Analysis of tumor samples from over 130 lung and pancreatic cancer patients linked high LCN2 levels to a median survival of 52 months, compared to 79 months for patients with low levels.
- The study, published in Nature on February 18, 2026, implicates the integrated stress response (ISR) and ATF4 in LCN2 production and tumor immune evasion.
The big picture
This research highlights a novel mechanism by which tumors evade the immune system, offering a potential new therapeutic target. The discovery of LCN2's role in immunosuppression could significantly impact the development of next-generation immunotherapies, particularly for aggressive cancers like lung and pancreatic cancer, which have historically shown limited response to existing treatments. The findings also underscore the importance of understanding cellular stress responses in cancer progression and immune evasion.
What we're watching
- Clinical Trials
- The translation of these promising mouse model results to human clinical trials will be critical to assess the efficacy and safety of LCN2-targeted therapies in lung and pancreatic cancer patients.
- Mechanism Validation
- Further research is needed to validate whether the LCN2/ATF4 pathway is active in other cancer types resistant to immunotherapy, potentially broadening the therapeutic application.
- Commercialization
- The involvement of multiple co-founders and advisors with equity stakes in related biotech companies (Aethon Therapeutics, Revalia Bio) suggests potential for rapid commercialization and licensing opportunities.
Related topics